The Multiple Myeloma program is part of the Hematologic Oncology (Blood Cancers) Treatment Center. Our specialists are highly experienced in treating patients with multiple myeloma.
The Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics provides comprehensive care to patients with multiple myeloma, including promising new therapies through clinical trials rooted in an approach that brings laboratory discoveries quickly to the clinical setting. We conduct an active program of basic and clinical research aimed at improving the outcomes of multiple myeloma.
The Bing Center for Waldenström's macroglobulinemia provides comprehensive, state-of-the-art care, including promising new therapies through clinical trials, to patients with Waldenström's macroglobulinemia and related IgM disorders.
We provide a comprehensive range of services for patients, including:
The program encompasses physicians, clinicians and a large, international team of laboratory-based and clinical investigators who are striving to find more effective therapies. Physicians work closely with research scientists in a "bench-to-bedside" approach that identifies promising new treatments by rapidly translating laboratory discoveries into the clinical setting.
Kenneth C. Anderson, MD, Program DirectorPaul G. Richardson, MD, Clinical Program Leader and Director of Clinical ResearchJacob Laubach, MD, Clinical DirectorNikhil C. Munshi, MD, Director of Basic and Correlative Science
Kenneth C. Anderson, MDJorge J. Castillo, MDIrene Ghobrial, MDJacob Laubach, MDClaudia Paba-Prada, MDPaul G. Richardson, MDRobert L. Schlossman, MDSteven P. Treon, MD, PhD
Dharminder Chauhan, PhDRuben Carrasco, MD, PhDTeru Hideshima, MD, PhDConstantine Mitsiades, MD, PhDYu-tzu Tai, PhD
Laura Amweg, RNKathleen Colson, RNKristen Cummings, RNVirginia Dalton, NPHeidi DiPietro, RNDeborah Doss, RN, BSNKathleen Finn, RNTina Flaherty, NPMeghan Leahy, RNEmily Lowery, NPMary McKenney, NPKim Noonan, NPEileen Regan, NP
The Lipper Center and LeBow Institute for Myeloma Therapeutics encompass a large, international team of laboratory-based and clinical investigators who are striving to find more effective therapies for multiple myeloma and, someday, a cure. At any given time, dozens of studies and clinical trials for multiple myeloma are underway.
Our program is a founding institution of the Multiple Myeloma Research Consortium (MMRC), which brings together distinguished researchers and world-renowned academic institutions to speed translation of research to clinical care for myeloma patients.
The center's research in the laboratory and the clinic is focused on several areas. These include investigations of the genetic abnormalities of myeloma cells; studies of the complex signaling that enables myeloma cells to grow and resist both conventional chemotherapy and novel therapy; efforts to unleash the power of the immune system against myeloma; and explorations of the way in which myeloma cells interact with their environment in the bone marrow and outside the marrow compartment. The mission of this research is to identify and validate novel targets in myeloma, so that new therapies aimed at these targets can be developed, leading to improved outcomes and a cure.
The center offers patients access to a wide range of clinical research trials. These include studies aimed at improving the outcomes of patients undergoing high-dose chemotherapy and stem cell transplantation, as well as trials using agents like thalidomide and its immunomodulatory derivatives, proteasome inhibitors, which attempt to kill myeloma cells directly and also make it impossible for them to grow in the marrow "neighborhood." The center also has clinical research trials evaluating supportive therapies, such as bisphosphonates.
Multiple Myeloma: 617-632-3823 or 617-632-5138, or use this online form to make an appointment.
You may schedule your first appointment for as soon as the next day. After scheduling, one of our nurses will call you to answer your questions and help you prepare for the appointment.
Contact your doctor directly, or for general inquiries, call the Hematologic Malignancies program at 617-632-6140.
Hematologic Malignancies DivisionDana-Farber Cancer Institute450 Brookline AvenueBoston, MA 02215
Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215 | Call us toll-free: